Life sciences tools company with ~10 employees and roughly $2M in revenue, providing cell-based assay reagents, custom products, and research services to NIH, academic labs, biotech, and large pharma, including Pfizer and Novavax. Core business is profitable and high-margin, with heavy reinvestment in R&D to expand the product portfolio. Key growth area is organoids — brain, heart, and other human model systems — positioned to benefit from increasing industry adoption of non-animal testing. This is an off-market opportunity, and we expect to introduce the owner to only a small number of buyers we believe are a strong fit.